Development of a Commercial Manufacturing Process for Vepdegestrant, an Orally Bioavailable PROTAC Estrogen Receptor Degrader for the Treatment of Breast Cancer
1. 系统已在2025-08-13 18:49:53对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: https://doi.org/10.1021/acs.oprd.4c00362
文献链接: https://pubs.acs.org/doi/10.1021/acs.oprd.4c00362
其他信息:
出版社: American Chemical Society (ACS)
作者: Steve Avery; Jamie M. Buske; Doris Chen; Herman Chen; Xin Chen; Andrew R. Davidson; Jean-Nicolas Desrosiers; Hanqing Dong; Noalle Fellah; David F. Fernández; John Grosso; Lu Han; Teri Hochdorfer; Amber M. Johnson; Brian P. Jones; Maciej Kalinowski; Katherine D. Launer-Felty; Jorge Lopez; Teresa Makowski; Carolyn Mastriano; Truong N. Nguyen; Nitinchandra D. Patel; Zhihui Peng; Tyler Potter; Robert P. Pritchard; Anil M. Rane; Max Reeve; Margaret C. Richins; Chase A. Salazar; John J. Salisbury; Robert Simpson; Liza Tabshey; Erin J. Tweed; Paul G. Wahome; Nancy Walsh-Sayles; Jordan A. Willie; Ethan Wood
全文下载地址: https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.4c00362
